Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885820 · ClinicalTrials.gov registry record · Phase 4
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT00885820 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 240 participants.
The verdict
NCT00885820, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection versus a non-protocol biopsy control group.
Interventions
- DRUG Tacrolimus
- DRUG MMF
- DRUG Corticosteroids (Prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885820
The ClinicalTrials.gov registry entry for NCT00885820 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00885820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885820 about?
NCT00885820 is a clinical study titled "Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection". This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection versus a non-protocol biopsy control group.
What is the current status of trial NCT00885820?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2001-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00885820?
The interventions under investigation include: Tacrolimus (DRUG), MMF (DRUG), Corticosteroids (Prednisone) (DRUG).
Who is sponsoring clinical trial NCT00885820?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.